Information Provided By: 
Fly News Breaks for July 21, 2017
RVNC
Jul 21, 2017 | 08:23 EDT
Cantor Fitzgerald analyst Louise Chen started Revance Therapeutics with an Overweight rating and $50 price target. The analyst sees positive news flow for the company's key programs in development driving both estimates and the shares higher. Chen expect Revance to report positive results before the end of the year for its Phase 3 pivotal trials for glabellar lines and Phase 2 results for its new indication, plantar fasciitis.
News For RVNC From the Last 2 Days
There are no results for your query RVNC
